X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (426) 426
cardiac & cardiovascular systems (324) 324
male (257) 257
female (253) 253
middle aged (213) 213
aged (177) 177
index medicus (174) 174
treatment outcome (174) 174
stents (122) 122
angioplasty (94) 94
time factors (91) 91
peripheral vascular disease (90) 90
cardiovascular (86) 86
abridged index medicus (79) 79
thrombosis (78) 78
drug-eluting stents (75) 75
drug therapy (74) 74
platelet aggregation inhibitors - therapeutic use (74) 74
angioplasty, balloon, coronary (72) 72
risk factors (70) 70
coronary angiography (67) 67
heart attacks (67) 67
stent (64) 64
follow-up studies (61) 61
mortality (61) 61
cardiology (59) 59
cardiology and cardiovascular medicine (59) 59
care and treatment (59) 59
double-blind method (58) 58
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (58) 58
prospective studies (57) 57
percutaneous coronary intervention (55) 55
internal medicine (54) 54
cardiovascular disease (53) 53
drug therapy, combination (53) 53
hematology (52) 52
implantation (50) 50
coronary artery disease - therapy (49) 49
platelet aggregation inhibitors - administration & dosage (49) 49
coronary vessels (47) 47
adult (46) 46
coronary disease - therapy (46) 46
abciximab (45) 45
clinical trials (45) 45
outcomes (43) 43
myocardial infarction - therapy (42) 42
restenosis (42) 42
myocardial infarction (41) 41
disease (40) 40
randomized controlled trials as topic (40) 40
antibodies, monoclonal - therapeutic use (39) 39
prognosis (39) 39
analysis (38) 38
transluminal angioplasty (38) 38
prosthesis design (37) 37
risk assessment (37) 37
acute coronary syndromes (36) 36
clinical outcomes (35) 35
coronary heart disease (35) 35
myocardial infarction - drug therapy (35) 35
united states (35) 35
cardiac patients (34) 34
follow-up (34) 34
angioplasty, balloon, coronary - adverse effects (33) 33
everolimus (33) 33
medicine, general & internal (33) 33
acute myocardial-infarction (32) 32
immunoglobulin fab fragments - therapeutic use (32) 32
unstable angina (32) 32
heart attack (31) 31
metaanalysis (31) 31
platelet aggregation inhibitors - adverse effects (31) 31
electrocardiography (30) 30
intervention (30) 30
safety (30) 30
trial (30) 30
artery-disease (29) 29
usage (29) 29
dosage and administration (28) 28
dose-response relationship, drug (28) 28
myocardial infarction - mortality (27) 27
revascularization (27) 27
risk (27) 27
blood platelets (26) 26
myocardial-infarction (26) 26
therapy (26) 26
thrombolytic therapy (26) 26
ticlopidine - analogs & derivatives (26) 26
aged, 80 and over (25) 25
diabetes (25) 25
myocardial infarction - etiology (25) 25
patient outcomes (25) 25
angioplasty, balloon, coronary - methods (24) 24
clopidogrel (24) 24
coronary artery disease (24) 24
drug-eluting stent (24) 24
ischemia (24) 24
randomized trial (24) 24
aspirin (23) 23
coronary artery disease - diagnostic imaging (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10034, pp. 2218 - 2225
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1609 - 1620
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 20, pp. 2211 - 2221
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 59, Issue 25, pp. 2344 - 2353
Objectives The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)–lowering efficacy of 5 SAR236553/REGN727... 
Cardiovascular | Internal Medicine | statin | low-density lipoprotein cholesterol | safety | apolipoprotein-B | PCSK9 | SAR236553/REGN727 | hypercholesterolemia | CUTANEOUS VASCULITIS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | CHOLESTEROL | CARDIOVASCULAR OUTCOMES | LOW-DENSITY-LIPOPROTEIN | PREVENTION | REDUCTION | DISEASE | 14 RANDOMIZED-TRIALS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - blood | Double-Blind Method | Proprotein Convertases - metabolism | Treatment Outcome | Anticholesteremic Agents - adverse effects | Drug Synergism | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Serine Endopeptidases - metabolism | Proprotein Convertase 9 | Care and treatment | Serine | Low density lipoproteins | Antibodies | Thrombin | Lipoprotein A | Cholesterol | Cardiovascular agents | Antilipemic agents | Viral antibodies | Complications and side effects | Hypercholesterolemia | Proteases | Monoclonal antibodies | Universities and colleges | Laboratories | Lipids | Triglycerides | Lipoproteins | Pain | Influenza | Patient safety | Population | Mutation | Clinical medicine | Diabetes | Statins
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 16, pp. 1735 - 1749
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2010, Volume 56, Issue 12, pp. 919 - 933
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents
Journal Article